{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T20:57:38Z","timestamp":1775509058978,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Overweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction among adults with and without diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Data were retrieved from six electronic databases: PubMed, Web of Science, Scopus, Cochrane Library, ClinicalTrial.gov, and Google Scholar, and manually searched from the included references. The data were synthesized using a random effect model. This analysis was performed in the R programming language using the Meta package.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of seven RCTs involving 680 participants were included in this study. Mazdutide was more effective in reducing body weight (mean difference [MD]= -6.22%, 95% confidence interval [CI]: -8.02% to -4.41%, I<jats:sup>2<\/jats:sup> = 90.0%), systolic blood pressure (MD = -7.57 mmHg, 95% CI: -11.17 to -3.98 mmHg, I<jats:sup>2<\/jats:sup> = 46%), diastolic blood pressure (MD = -2.98 mmHg, 95% CI: -5.74 to -0.22 mmHg, I<jats:sup>2<\/jats:sup> = 56%), total cholesterol (MD = -16.82%, 95% CI: -24.52 to -9.13%, I<jats:sup>2<\/jats:sup> = 61%), triglycerides (MD = -43.29%, 95% CI: -61.57 to -25.01%, I<jats:sup>2<\/jats:sup> = 68%), low-density lipoprotein (MD= -17.07%, 95% CI: -25.54 to -8.60%, I<jats:sup>2<\/jats:sup> = 53%), and high-density lipoprotein (MD = -7.54%, 95% CI: -11.26 to -3.83%, I<jats:sup>2<\/jats:sup> = 0%) than placebo. Mazdutide was associated with reduced hemoglobin A1c (HbA1c) and fasting plasma glucose in participants with type 2 diabetes. In the subgroup and meta-regression analyses, weight reduction was more significant in non-diabetics compared to diabetics, and in those who received a longer treatment duration (24 weeks) than in those on shorter durations (12-20 weeks). Participants who received Mazdutide had a higher risk of transient mild or moderate gastrointestinal side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mazdutite appears to be effective in weight reduction among patients with and without diabetes, and it has an advantage over other associated comorbidities. However, it was associated with mild or moderate gastrointestinal side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=403859<\/jats:uri>, identifier CRD42023403859.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1309118","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:43:40Z","timestamp":1708357420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"15","author":[{"given":"David Lubasi","family":"Nalisa","sequence":"first","affiliation":[]},{"given":"Nelson","family":"Cuboia","sequence":"additional","affiliation":[]},{"given":"Eman","family":"Dyab","sequence":"additional","affiliation":[]},{"given":"Idongesit Linus","family":"Jackson","sequence":"additional","affiliation":[]},{"given":"Habimana Jean","family":"Felix","sequence":"additional","affiliation":[]},{"given":"Pantaleon","family":"Shoki","sequence":"additional","affiliation":[]},{"given":"Mary","family":"Mubiana","sequence":"additional","affiliation":[]},{"given":"Mariam","family":"Oyedeji-Amusa","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"B1","unstructured":"LobsteinT\n            BrinsdenH\n            NeveuxM\n          World obesity atlas 20222022"},{"key":"B2","volume-title":"Overcoming obesity: an initial economic analysis","author":"Dobbs","year":"2014"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12510","article-title":"Obesity: Risk factors, complications, and strategies for sustainable long-term weight management","volume":"29","author":"Fruh","year":"2017","journal-title":"J Am Assoc Nurse Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.243","article-title":"Moderate and severe obesity have large differences in health care costs","volume":"12","author":"Andreyeva","year":"2004","journal-title":"Obes Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-242","article-title":"The direct and indirect costs of both overweight and obesity: a systematic review","volume":"7","author":"Dee","year":"2014","journal-title":"BMC Res Notes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/jehp.jehp_216_20","article-title":"Lifestyle-related advice in the management of obesity: A step-wise approach","volume":"9","author":"Chopra","year":"2020","journal-title":"J Educ Health Promot"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6118\/jmm.2014.20.3.90","article-title":"Pharmacotherapy for obesity","volume":"20","author":"Joo","year":"2014","journal-title":"J Menopausal Med"},{"key":"B8","volume-title":"Obesity surgery indications and contraindications","author":"Stahl","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B10","volume-title":"Pharmacologic Therapy For Obesity","author":"Sombra","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-019-00328-6","article-title":"Pharmacotherapy of obesity: limits and perspectives","volume":"19","author":"Rosa-Gon\u00e7alves","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin","volume":"3","author":"Pocai","year":"2014","journal-title":"Mol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3667","article-title":"Obesity and hypertension","volume":"12","author":"Jiang","year":"2016","journal-title":"Exp Ther Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1007\/s00125-022-05755-w","article-title":"Oxyntomodulin analog LY3305677 (LY) improves glycaemic control and weight loss in healthy volunteers and subjects with type 2 diabetes","volume":"65","author":"Benson","year":"2022","journal-title":"Diabetes"},{"key":"B18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.diabres.2022.109271","article-title":"IDF21-0323 Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study","volume":"186","author":"Yang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Sara","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2023","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/s41467-022-31328-x","article-title":"A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935823","article-title":"Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Gao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: A systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108656","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"172","author":"Li","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2022.89292","article-title":"A review of current guidelines for the treatment of obesity","volume":"28","author":"Cornier","year":"2022","journal-title":"Am J Manag Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1331\/japha.2014.14502","article-title":"Reprint: 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: A narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100076","article-title":"Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review","volume":"7","author":"Bays","year":"2023","journal-title":"Obes Pillars"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000001275","article-title":"Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study","volume":"35","author":"Kumarathurai","year":"2017","journal-title":"J Hyperten"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/phy2.112","article-title":"Oxyntomodulin increases intrinsic heart rate through the glucagon receptor","volume":"1","author":"Mukharji","year":"2013","journal-title":"Physiol Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1309118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:43:46Z","timestamp":1708357426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1309118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":41,"alternative-id":["10.3389\/fendo.2024.1309118"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1309118","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"article-number":"1309118"}}